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OBJECTIVE—Individuals with type 1 diabetes have a less
atherogenic fasting lipid proﬁle than those without diabetes but
paradoxically have increased rates of cardiovascular disease
(CVD). We investigated differences in lipoprotein subfraction
cholesterol distribution and insulin resistance between subjects
with and without type 1 diabetes to better understand the
etiology of increased CVD risk.
RESEARCH DESIGN AND METHODS—Fast protein liquid
chromatography was used to fractionate lipoprotein cholesterol
distribution in a substudy of the Coronary Artery Calciﬁcation in
Type 1 Diabetes (CACTI) study (n  82, age 46  8 years, 52%
female, 49% with type 1 diabetes for 23  8 years). Insulin
resistance was assessed by a hyperinsulinemic-euglycemic clamp.
RESULTS—Among men, those with type 1 diabetes had less
VLDL and more HDL cholesterol than control subjects (P 
0.05), but among women, those with diabetes had a shift in
cholesterol to denser LDL, despite more statin use. Among
control subjects, men had more cholesterol distributed as VLDL
and LDL but less as HDL than women; however, among those
with type 1 diabetes, there was no sex difference. Within sex and
diabetes strata, a more atherogenic cholesterol distribution by
insulin resistance was seen in men with and without diabetes, but
only in women with type 1 diabetes.
CONCLUSIONS—The expected sex-based less atherogenic li-
poprotein cholesterol distribution was not seen in women with
type 1 diabetes. Moreover, insulin resistance was associated with
a more atherogenic lipoprotein cholesterol distribution in all men
and in women with type 1 diabetes. This lipoprotein cholesterol
distribution may contribute to sex-based differences in CVD in
type 1 diabetes. Diabetes 59:1771–1779, 2010
C
ardiovascular disease (CVD) is the major cause
of mortality in type 1 diabetes, and, in addition
to glycemic control and blood pressure, dyslip-
idemia is an important and modiﬁable CVD risk
factor (1–8). Curiously, despite higher rates of CVD in type
1 diabetes, including a relative loss of sex protection in
women with type 1 diabetes (9–11), and the role of
dyslipidemia as a determinant of CVD (8), individuals with
type 1 diabetes have similar or less atherogenic lipid
proﬁles than age-, sex-, and BMI-matched nondiabetic
subjects (5,12). This paradox is well known (13), but few
data exist to explain this phenomenon. Lipoprotein differ-
ences in type 1 diabetes have been investigated in the
Diabetes Control and Complications Trial (DCCT)/Epide-
miology of Diabetes Interventions and Complications
(EDIC) study but lack a nondiabetic comparison group
(14–17).
Furthermore, it has been known for nearly 40 years that
insulin resistance is a prominent CVD risk factor in type 1
diabetes (18,19), and recent studies have demonstrated
increased insulin resistance in people with type 1 diabetes
compared with age-, sex-, and BMI-matched nondiabetic
control subjects (20,21). The hyperinsulinemic-euglycemic
clamp is considered the “gold standard” method for mea-
suring insulin resistance in a wide variety of circum-
stances (22), especially in individuals with type 1 diabetes,
in whom prediction models of insulin resistance that rely
on glucose and insulin levels cannot be used. The effect of
insulin resistance on lipoproteins has been investigated in
individuals with type 2 diabetes and in those without
diabetes (23–25), but to our knowledge, the effect of
insulin resistance on lipoproteins has not been investi-
gated in individuals with type 1 diabetes.
Therefore, to examine beyond the ability of the standard
fasting lipid proﬁle to assess CVD risk, we investigated
differences in lipoprotein subfraction cholesterol distribu-
tion between subjects with and without type 1 diabetes
and how insulin resistance affects this distribution. We
hypothesized that differences would exist in lipoprotein
subfraction cholesterol distribution by type 1 diabetes
status, and, furthermore, we hypothesized that subjects
with more insulin resistance as measured by a hyperinsu-
linemic-euglycemic clamp would have a more atherogenic
lipoprotein subfraction cholesterol distribution.
RESEARCH DESIGN AND METHODS
Subjects were recruited from the Coronary Artery Calciﬁcation in Type 1
Diabetes (CACTI) study cohort for a hyperinsulinemic-euglycemic clamp
substudy. Inclusion criteria for initial enrollment of type 1 diabetic subjects in
the CACTI study were age 19–56 years, no history of coronary artery disease
(CAD), receiving insulin therapy within 1 year of diagnosis and current insulin
therapy, diagnosis before age 30 years, and diabetes duration 10 years (4).
Nondiabetic control subjects were recruited from friends and spouses and
were of similar age and had no history of CAD. We present data from 82
subjects (40 type 1 diabetic and 42 nondiabetic control subjects) recruited
between 2005 and 2008 who underwent a hyperinsulinemic-euglycemic clamp
after their 6-year CACTI follow-up visit. Inclusion criteria for the clamp
substudy included A1C 9.5%, albumin excretion rate 200 g/min, and
triglycerides 400 mg/dl. Reported physical activity and computed tomo-
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diabetes.diabetesjournals.org DIABETES, VOL. 59, JULY 2010 1771graphic measures of visceral fat from the third CACTI visit (2005–2008) are
presented (26). Subjects in the clamp study were similar in age, BMI, visceral
fat, and physical activity to subjects in the full cohort seen at the third CACTI
visit within sex and diabetes strata. All participants provided informed
consent, and the study was approved by the Colorado Combined Institutional
Review Board.
Hyperinsulinemic-euglycemic clamp visit. Subjects were maintained for 3
days before their study day on a provided diet with standardized macronutri-
ent composition (50% carbohydrate, 20% protein, and 30% fat) and were asked
to refrain from vigorous physical activity. Computed tomography dual-energy
X-ray absorptiometry scans for body composition measures were performed.
Subjects were admitted to the inpatient clinical research unit before a
standard dinner the evening before their clamp. Women who were premeno-
pausal were scheduled to have their clamp performed between days 2 and 10
of the menstrual cycle. Type 1 diabetic subjects were instructed to take their
last long-acting insulin injections at least 12 h before admission. A standard
dinner was provided on the unit, and subjects then fasted overnight and
through the clamp protocol. Type 1 diabetic subjects received their rapid-
acting insulin for dinner per their usual regimen. All type 1 diabetic subjects
were maintained overnight on intravenous regular insulin with adjustments by
a standard protocol to maintain near euglycemia until starting the clamp in the
morning. Blood samples for determination of baseline hormone and substrate
concentrations (insulin, glucose, C-peptide, free fatty acid, glycerol, and
lactate) were drawn over the ﬁnal 30 min before initiation of the clamp
protocol. A three-stage hyperinsulinemic-euglycemic clamp was then initiated
and continued for the next 4.5 h using the method of DeFronzo et al. (22).
Brieﬂy, a primed continuous infusion of insulin was administered at 4
mU/m
2/min for 1.5 h, 8 mU/m
2/min for 1.5 h, and then 40 mU/m
2/min for the
ﬁnal 1.5 h. A variable amount of 20% dextrose was infused to maintain blood
glucose 90 mg/dl. Arterialized blood was sampled every 5 min for bedside
determination of glucose concentration (Analox, Lunenburg, MA), and the
dextrose infusion was adjusted as necessary. Arterialized blood samples were
taken twice during the last 10 min of each stage of the clamp for hormone and
substrate measurements as above. A hyperinsulinemic-euglycemic steady
state was achieved in the ﬁnal 30 min of the clamp, and the glucose infusion
rate (milligrams per kilogram per minute) was measured and is presented in
these data as milligrams per kilogram fat-free mass (FFM) per minute. Fasting
plasma samples obtained before initiation of the clamp were stored at 80°C
and then thawed immediately before fast protein liquid chromatography
(FPLC) analysis in all subjects in the clamp study who had available samples.
Lipoprotein analysis. Individual subject’s EDTA plasma samples (250 l)
were chromatographed using two Superose 6 columns in series (27), and 51
0.5-ml fractions were collected. Cholesterol was measured in each fraction
using a commercially available kit (Cayman Chemical Company, Ann Arbor,
MI) following procedures outlined in the package insert. An example of an
individual FPLC lipoprotein subfraction cholesterol distribution proﬁle with
fractions labeled as VLDL, LDL, and HDL (increasing density from left to right)
is shown in Fig. 1.
Statistical analyses. Variables were examined for normality and nonnor-
mally distributed variables were log-transformed for analysis. Differences in
clinical and clamp parameters between type 1 diabetic and nondiabetic
subjects and between men and women within each group were examined
using unpaired Student t tests. Differences in categorical variables were
examined using 
2 tests. P  0.05 was considered statistically signiﬁcant. SAS
(version 9.2) was used for analyses, and Sigma Plot was used for generating
difference ﬁgures.
Methods for presentation of ﬁgures. The cholesterol content in each
fraction obtained from the FPLC is expressed as a percentage of the total
cholesterol in all subfractions to adjust for differences in total cholesterol
levels among subjects, adapting the methodology previously used in DCCT/
EDIC (14). This is calculated by summing the cholesterol for an individual in
all 51 fractions and expressing the result for each fraction as the cholesterol
in that fraction divided by the summed cholesterol and multiplied by 100. To
test the signiﬁcance of differences in cholesterol distributions among groups
of subjects, a difference plot is generated by subtracting the mean percent
cholesterol value of each fraction in one group from the mean percent
cholesterol value in the same fraction of the second group and determining
the 95% CI for this difference. A difference in fractional cholesterol content
between groups is signiﬁcant (P  0.05) when the 95% CI does not cross the
zero line.
RESULTS
Characteristics of study subjects are presented in Table 1
stratiﬁed by sex and type 1 diabetes status. As previously
reported in the full CACTI cohort, type 1 diabetic subjects
had a less atherogenic fasting lipid proﬁle than nondia-
betic subjects (5). For example, in both male and female
subjects with type 1 diabetes, LDL cholesterol was 30
mg/dl lower than in nondiabetic subjects. As expected,
type 1 diabetic subjects had a higher preclamp fasting
glucose and insulin level than nondiabetic subjects, but
there were no differences at the end of the clamp. Further-
more, type 1 diabetic subjects were more insulin resistant
than nondiabetic subjects, for both women (6.2  3.4 vs.
15.5  4.8 mg/kg FFM/min; P  0.0001) and men (5.4  3.7
vs. 10.0  5.2 mg/kg FFM/min; P  0.004). Type 1 diabetic
subjects were also more likely to be receiving statin
treatment (women 52 vs. 9%, P  0.002; men 68 vs. 15%,
P  0.0001) and have higher A1C (women 7.5  0.9 vs.
5.4  0.3%, P  0.0001; men 7.5  0.8 vs. 5.4  0.3%, P 
0.0001). Among women, there was no difference in the
prevalence of menopause or the use of oral contraceptive
hormones by diabetes status. There was no difference in
BMI, reported physical activity, or visceral fat by sex or
diabetes status.
Differences by type 1 diabetes. The mean lipoprotein
subfraction cholesterol distributions are displayed within
subjects with type 1 diabetes (Fig. 2A, hatched line) and
within nondiabetic control subjects (Fig. 2A, solid line).
As shown in Fig. 2B, subjects with type 1 diabetes had less
VLDL and more HDL cholesterol than control subjects
(P  0.05 for both). Next, differences by sex in lipoprotein
subfraction cholesterol distribution are displayed within
subjects with type 1 diabetes (Fig. 3A) and within nondi-
abetic control subjects (Fig. 3B). Nondiabetic control men
had more cholesterol distributed as VLDL and LDL but less
as HDL than women (P  0.05), as expected, but no
signiﬁcant differences existed by sex in type 1 diabetic
subjects.
Differences by sex. We next investigated differences in
lipoprotein subfraction cholesterol distribution by type 1
diabetes status in men (Fig. 4A) and women (Fig. 4B).
Among men, those with type 1 diabetes had less VLDL and
more HDL cholesterol than control subjects. In women,
however, those with type 1 diabetes had more LDL cho-
lesterol with an apparent shift of cholesterol distribution
within LDL to smaller (atherogenic) LDL fractions in those
with diabetes compared with those without.
Glycemia and statins. Because statin use and glycemic
control are both likely major confounders of lipoprotein
subfraction cholesterol distribution differences by diabe-
tes status, we next examined the differences by statin use
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FIG. 1. FPLC lipoprotein cholesterol distribution in a 49-year-old
nondiabetic woman with a fasting lipid panel total cholesterol of 152
mol/l, LDL cholesterol of 84 mol/l, HDL cholesterol of 53, and
triglycerides of 74 mol/l and not on statin therapy.
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glycemic control as measured by the highest versus lowest
tertiles of A1C (data not shown). No differences in the
fasting lipid proﬁle existed within type 1 diabetic men and
women based on statin status. LDL cholesterol was similar
in men with type 1 diabetes by statin status (72  34 vs.
69  22 mg/dl, P  0.82) and in women with type 1
diabetes (64  24 vs. 67  26 mg/dl, P  0.81). However,
men with type 1 diabetes in the lowest tertile of A1C
(7.2%) had less cholesterol distributed in LDL compared
with men with type 1 diabetes in the highest A1C tertile
(8.0%), but there were no differences in VLDL or HDL
cholesterol. In women with type 1 diabetes, no difference
existed in lipoprotein subfraction cholesterol distribution
between the lowest A1C tertile (6.9%) and the highest A1C
tertile (8.2%).
Insulin resistance. To further investigate these differ-
ences and to test the hypothesis that insulin resistance
affects lipoprotein subfraction cholesterol distribution, we
plotted the differences between the highest and lowest
tertiles of insulin resistance as measured by the hyperin-
sulinemic-euglycemic clamp protocol within each sex and
type 1 diabetes strata. Differences in lipoprotein subfrac-
tion cholesterol distribution by these strata were as fol-
lows. For men with type 1 diabetes, those with the most
insulin resistance compared with those with the least
insulin resistance had a shift to increased cholesterol in
denser LDL and HDL (Fig. 5A). For male control subjects,
those with the most insulin resistance compared with
those with the least insulin resistance had more VLDL
cholesterol as well as a shift to increased cholesterol in
denser LDL and HDL (Fig. 5B). For women with type 1
diabetes, those with the most insulin resistance compared
with those with the least insulin resistance had more
cholesterol distributed in VLDL and less distributed in
HDL (Fig. 5C). However, in contrast, for female control
subjects, there were no differences in lipoprotein subfrac-
tion cholesterol distribution between subjects with the
most and least insulin resistance (Fig. 5D).
Also, of note, the pattern for differences in the largest
(but not the smallest) lipoprotein HDL cholesterol distri-
bution by insulin resistance tertiles for women with type 1
diabetes in Fig. 5D was similar to that of men with type 1
diabetes (Fig. 5A) and male control subjects (Fig. 5B)b y
insulin resistance tertiles. Therefore, it appears that the
effect of insulin resistance on lipoprotein subfraction
cholesterol distribution was similar in men with and
without type 1 diabetes (Fig. 5A and B) and also in women
with type 1 diabetes (Fig. 5D) but not in nondiabetic
women (Fig. 5C).
Visceral fat. Finally, visceral fat was more strongly cor-
related with glucose infusion rate in type 1 diabetic
subjects (r  0.51, P  0.017, in women and r  0.43,
P  0.066, in men) than in nondiabetic subjects (r 
0.29, P  0.19, and r  0.24, P  0.31, in women and
men, respectively). A modest effect was observed on HDL
cholesterol distribution when the highest visceral fat ter-
tiles were compared with the lowest visceral fat tertiles in
men and women with type 1 diabetes (Fig. 6A–D).
DISCUSSION
The main ﬁndings of this study are that men with type 1
diabetes have a less atherogenic lipoprotein subfraction
cholesterol distribution than nondiabetic men, perhaps
due to increased statin use, but women with type 1
diabetes have a more atherogenic distribution compared
with nondiabetic women with more LDL cholesterol and
an apparent shift of cholesterol to a smaller LDL despite
the higher prevalence of statin therapy. Furthermore,
women with type 1 diabetes have a lipoprotein subfraction
cholesterol distribution similar to that of type 1 diabetic
men not the less atherogenic proﬁle that is the expected
sex-based difference seen in the nondiabetic control sub-
jects. Next, when we investigated the association of insu-
lin resistance and lipoprotein subfraction distribution, a
pronounced association of higher insulin resistance with a
more atherogenic lipoprotein subfraction cholesterol dis-
TABLE 1
Baseline characteristic of subjects by type 1 diabetes status and sex
Women Men
Type 1 diabetes Control P Type 1 diabetes Control P
n 21 22 19 20
Age (years) 44  94 4  8 0.75 47  10 47  6 0.89
Type 1 diabetes duration (years) 22  8N A N A 2 3  8N A N A
Glucose infusion rate (mg/kg FFM/min) 6.2  3.4 15.5  4.8 0.0001 5.4  3.7 10.0  5.2 0.004
A1C (%) 7.5  0.9 5.4  0.3 0.0001 7.5  0.8 5.4  0.3 0.0001
Fasting glucose (mg/dl) 109  19 92  6 0.0008 124  53 99  9 0.06
Final clamp glucose (mg/dl) 89  48 9  3 0.90 89  29 1  3 0.10
Baseline insulin (U/ml) 36  35 8  2 0.001 27  16 10  5 0.0002
Final clamp insulin (U/ml) 108  40 108  33 0.96 104  31 87  23 0.06
Body fat (%) 32.4  6.7 34.7  6.6 0.27 24.3  6.1 24.2  3.2 0.92
BMI (kg/m
2) 25.8  4.3 25.8  4.3 0.99 28.3  4.3 27.2  3.6 0.41
Visceral fat (cm
2) 10.5  0.6 10.5  0.3 0.93 10.9  0.4 11.0  0.5 0.31
Physical activity (log kcal) 7.2  1.3 7.4  1.1 0.52 7.3  1.0 7.5  0.8 0.50
Total cholesterol (mg/dl) 135  33 171  33 0.0009 145  32 171  25 0.007
HDL cholesterol (mg/dl) 56  13 57  10 0.74 61  30 45  9 0.03
Triglycerides (mg/dl) 69  42 99  40 0.02 70  22 126  73 0.003
LDL cholesterol (mg/dl) 66  25 95  29 0.0009 70  25 101  25 0.0004
Taking statins (%) 52 9 0.002 68 15 0.001
Oral contraceptive pill use (%) 86 73 0.46 NA NA NA
Postmenopausal (%) 19 32 0.49 NA NA NA
Data are means  SD or %. NA, not applicable.
D.M. MAAHS AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JULY 2010 1773tribution was noted among men with and without type 1
diabetes and in women with type 1 diabetes. These data
are novel because most previous investigations of lipopro-
tein distribution in people with type 1 diabetes lacked a
nondiabetic control group, and, furthermore, the role of
insulin resistance was not investigated. Therefore, these
ﬁndings suggest that the fasting lipid proﬁle may inade-
quately assess CVD risk in people with type 1 diabetes and
that insulin resistance may play an important role in these
differences, especially in women with type 1 diabetes.
When we examined the effect of glycemic control in type
1 subjects, there was only a minimal effect on lipoprotein
subfraction cholesterol distribution (data not shown). The
type 1 diabetic subjects had reasonably good glycemic
control with a small difference between the highest and
lowest A1C tertiles, perhaps explaining this limited asso-
ciation of glycemic control with lipoprotein subfraction
cholesterol distribution.
Not unexpectedly, there were no differences in LDL
subfraction cholesterol distribution in type 1 diabetic
subjects based on statin use (data not shown). Previous
studies have shown that statins do not change the LDL
cholesterol subfraction distribution (28,29), whereas
higher doses of a potent statin, that is, rosuvastatin, can
increase buoyant HDL more than small HDL (30). We also
did not ﬁnd a difference in the fasting LDL cholesterol in
subjects with type 1 diabetes by statin treatment. It is
likely that the type 1 diabetic subjects receiving statin
treatment were being treated because of previous lipid
abnormalities. Regardless of statin treatment, the type 1
diabetic subjects had mean LDL cholesterol levels near 70
mg/dl. Moreover, an effect of statins on LDL cholesterol
distribution would be unexpected. In fact, this emphasizes
the ﬁnding of a more atherogenic lipoprotein proﬁle seen
in women with type 1 diabetes compared with nondiabetic
women, despite the type 1 diabetic women being much
more likely to be taking statins. In contrast, on the fasting
lipid proﬁle, both men and women with type 1 diabetes
had LDL cholesterol 30 mg/dl lower than nondiabetic
subjects. This highlights how the fasting lipid proﬁle may
not adequately represent CVD risk in people with type 1
diabetes. Because only ﬁve nondiabetic subjects were
taking statins, we are unable to compare the effect of
statins on lipoprotein subfraction cholesterol distribution
between type 1 diabetic and nondiabetic subjects.
Our data on differences in lipoprotein subfraction cho-
lesterol distribution between type 1 diabetic and nondia-
betic control subjects are consistent with previous reports
using nuclear magnetic resonance (NMR) (31) and of a
less atherogenic lipid proﬁle in people with type 1 diabetes
compared with nondiabetic control subjects (5,12,13).
A 
B
Fraction number
%
 
C
h
o
l
e
s
t
e
r
o
l
0 1 02 03 04 05 0
50
0
5
10
VLDL
LDL
HDL
Fraction number
0 1 02 03 04 0
%
 
C
h
o
l
e
s
t
e
r
o
l
-5.0
-2.5
0.0
2.5
5.0
VLDL LDL HDL
FIG. 2. A: Means of FPLC lipoprotein cholesterol distribution in
subjects with type 1 diabetes (hatched line) and nondiabetic control
subjects (solid line). B: Differences in FPLC lipoprotein distribution
by type 1 diabetes status (type 1  nondiabetic, so that a mean above
the zero indicates more cholesterol in type 1 diabetic subjects and a
mean below the zero line indicates less). Arrows indicate fractions in
which statistically signiﬁcant differences exist.
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FIG. 3. A: Differences in FPLC lipoprotein distribution by sex in type 1
diabetic subjects (male type 1 diabetic  female type 1 diabetic). B:
Differences in FPLC lipoprotein distribution by sex in nondiabetic
subjects (male nondiabetic  female nondiabetic).
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in type 1 diabetes requires a clamp, the CACTI clamp
substudy provided a unique opportunity to investigate the
reported association of lipoprotein cholesterol distribu-
tion with insulin resistance in people with type 1 diabetes
to extend previous research (23–25) performed in subjects
without diabetes and those with type 2 diabetes. For
example, our results on the differences by diabetes status
or the differences by insulin resistance are greater than the
1% differences reported by Purnell et al. (14) in the
DCCT/EDIC cohort when the ﬁrst and fourth quartiles of
weight gain (a surrogate of insulin resistance) were com-
pared within treatment arms. The differences we report in
lipoprotein subfraction cholesterol distribution related to
the differences in insulin resistance are similar to or
greater than the magnitude of the differences in choles-
terol subfractions reported in the DCCT/EDIC cohort
between the intensively and conventionally treated arms
of the study in which there was a 2% difference in A1C.
However, unlike the DCCT, the CACTI study is an obser-
vational cohort. Thus, the association of glycemia, obesity,
and insulin resistance to lipoprotein metabolism and CVD
are complex in type 1 diabetes and require further
investigation.
Further data from the DCCT/EDIC study using NMR
lipoprotein analysis show that male sex and poor glycemic
control are associated with a more atherogenic lipoprotein
proﬁle (16), which is in turn associated with increased
carotid intima-media thickness (17) and renal dysfunction
(32). In contrast, Colhoun et al. (31) have reported a lack
of association between lipoprotein subclasses and particle
size with coronary artery calcium in adults with type 1
diabetes. The type 1 diabetic subjects had more large and
less small HDL than nondiabetic subjects (31), although
we observed this HDL effect only in men. Of note, in this
study, among people with type 1 diabetes, a sex difference
in lipoproteins was also reported; women with type 1
diabetes had less large and more small dense LDL and
reduced LDL size, and this effect of type 1 diabetes on LDL
size was signiﬁcantly different in women than in men (31).
Also, our data are consistent with those reported by
Colhoun et al. and uniquely extend this ﬁnding by impli-
cating insulin resistance as part of the pathophysiologic
mechanism of sex differences in lipoproteins.
Additional data exist on lipoproteins and insulin resis-
tance in people with type 2 diabetes. Goff et al. (24) have
reported data from the Insulin Resistance Atherosclerosis
Study (IRAS) family study using NMR technology and an
intravenous glucose tolerance test to assess the associa-
tions between insulin resistance and lipoproteins in a
mixed-race cohort with type 2 diabetes, impaired glucose
tolerance, and normal glucose tolerance. They reported
associations of insulin resistance with a variety of lipopro-
tein measures (size and subclass concentrations) and
using factor analysis accounted for 41% of the variance
across lipoprotein measures, which was correlated with
insulin resistance (24). Similarly, Garvey et al. (23) re-
ported data on the association of glucose disposition rate
as determined by a hyperinsulinemic-euglycemic clamp to
lipoprotein sizes and concentrations (as measured by
NMR) in insulin-sensitive, insulin-resistant, and untreated
type 2 diabetic subjects. Insulin resistance, although not
type 2 diabetes per se, was associated with more athero-
genic lipoprotein size and subclass particle concentrations
for VLDL, LDL, and HDL, but these differences were not
apparent in conventional fasting lipid proﬁles (23).
Although lipid levels in patients with type 1 diabetes
have been found to be comparable to or better than those
in nondiabetic control subjects (lower total cholesterol,
LDL, and triglyceride and higher HDL) (5,12,13), adults
with type 1 diabetes still commonly have dyslipidemia and
are known to be at higher risk for atherosclerotic disease
and for worse outcomes of CVD compared with the
general population (7). Dyslipidemia is clearly a major risk
factor for atherosclerosis and CVD in adults with both type
1 and type 2 diabetes (8). The National Cholesterol Edu-
cation Program considers the presence of diabetes to be
the risk equivalent of a history of coronary disease with
similar goals for lipid lowering (33). Although the effec-
tiveness of statin treatment on elevated LDL cholesterol in
adults with type 2 diabetes is well established (8), no
clinical trials exist in people with type 1 diabetes, demon-
strating that LDL cholesterol reduction results in improved
CVD outcomes. However, the Heart Protection Study
included 615 subjects with type 1 diabetes and the magni-
tude of reduction in CVD events was similar in type 1 and
type 2 diabetic subjects, although this study was under-
powered to be statistically signiﬁcant in subgroup analysis
(34). There is consideration that lipids may be more
atherogenic in those with diabetes. Possible mechanisms
include differences in lipoprotein particle size, LDL oxida-
tion, and increased transvascular and macrophage LDL
transport in patients with type 1 diabetes (31,33,35).
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FIG. 4. A: Differences in FPLC lipoprotein distribution by type 1
diabetes in male subjects (male type 1 diabetic  male nondiabetic). B:
Differences in FPLC lipoprotein distribution by type 1 diabetes in
female subjects (female type 1 diabetic  female nondiabetic).
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diabetes but is not always considered as part of type 1
diabetes. Despite the relative lack of dyslipidemia and
obesity in type 1 diabetic patients, studies using the
hyperinsulinemic-euglycemic clamp have demonstrated
increased insulin resistance in type 1 diabetic patients
compared with nondiabetic individuals (20,21,36–39), and
glucose disposal rate was statistically signiﬁcantly associ-
ated with triglycerides (r  0.51, P  0.01) but not HDL
cholesterol (r  0.13) in a clamp study with 24 subjects
with type 1 diabetes (40). It has been proposed that this
increased insulin resistance may be due to the subcutane-
ous delivery of insulin in supraphysiologic doses in pa-
tients with type 1 diabetes (39). This treatment modality
may increase peripheral insulin resistance but would not
be expected to affect the liver and lipoprotein production
because subcutaneous insulin does not expose the liver
to high insulin levels as does endogenous insulin produc-
tion in hyperinsulinemic type 2 diabetic patients and
nondiabetic individuals. In the general population, insulin
resistance is an important component of accelerated ath-
erosclerosis (41). It is plausible that CAD develops earlier
in type 1 diabetic patients who are insulin resistant
(26,42,43). However, direct measurement of insulin resis-
tance in insulin-treated patients is difﬁcult and requires the
euglycemic insulin clamp approach with careful stabiliza-
tion of glycemia. Glucose clamps have good intrasubject
reproducibility but are time-consuming, costly, and labor-
intensive and, therefore, are difﬁcult to perform in large
epidemiologic trials. Methods for estimating insulin resis-
tance in nondiabetic individuals (homeostasis model as-
sessment and the quantitative insulin sensitivity check
index) have been developed but cannot be applied to
patients with type 1 diabetes because they are severely
insulin deﬁcient and therefore unable to secrete insulin in
response to glycemic challenge. Moreover, fasting plasma
insulin levels only reﬂect their exogenous insulin treat-
ment regimen.
This study does have limitations. Because of the time-
intensive nature of the hyperinsulinemic-euglycemic
clamp protocol, we have complete data on only these 82
subjects, and although they are representative of the full
CACTI cohort, they may not be representative of other
type 1 diabetic populations. However, this study is much
larger than most previous clamp studies performed in
individuals with type 1 diabetes and includes a nondiabetic
control group. Also, it is possible that the control women
in the least insulin resistance tertile were still sufﬁciently
insulin sensitive to not demonstrate a relationship be-
tween insulin resistance and an effect on lipoprotein
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FIG. 5. A: Differences in FPLC lipoprotein distribution by insulin resistance (highest vs. lowest tertiles) in male type 1 diabetic subjects. B:
Differences in FPLC lipoprotein distribution by insulin resistance (highest vs. lowest tertiles) in male nondiabetic subjects. C: Differences in
FPLC lipoprotein distribution by insulin resistance (highest vs. lowest tertiles) in female type 1 diabetic subjects. D: Differences in FPLC
lipoprotein distribution by insulin resistance (highest vs. lowest tertiles) in female nondiabetic subjects.
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diabetic subjects are well described, with 41% (44) and
45% (45) greater insulin sensitivity reported in women
compared with men, similar to the difference in our
nondiabetic subjects. Furthermore, we present data on
lipoprotein subfraction cholesterol distribution in fasting
samples collected before initiation of the hyperinsulinemic
clamp only, and the effects of insulin infusion on lipopro-
tein distribution cannot be examined in this study. Addi-
tionally, other analytes were not measured in the
lipoprotein subfractions such as triglycerides, and these
may differ by type 1 diabetes and insulin resistance and
represent future directions to investigate. Finally, the data
presented in this study are cross-sectional and so causa-
tion of the reported associations cannot be determined.
In conclusion, a less atherogenic lipoprotein proﬁle is
seen in men but not in women with type 1 diabetes. This is
in contrast to the well-described sex difference seen in
nondiabetic women who have a less atherogenic lipid and
lipoprotein proﬁle and lower rates of CVD, especially
before menopause. In men with and without type 1 diabe-
tes and in women with type 1 diabetes, insulin resistance
was associated with a more atherogenic lipoprotein pro-
ﬁle. These data suggest that differences in lipoprotein
cholesterol distribution may contribute to sex-based dif-
ferences in CVD risk in type 1 diabetes and that insulin
resistance may explain some of this increased relative risk
in women with type 1 diabetes. In general, our data reﬂect
the important need for further investigation of the contri-
bution of insulin resistance to lipoprotein metabolism and
CVD risk in patients with type 1 diabetes.
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